New therapeutic directions for advanced pancreatic cancer: Targeting the epidermal growth factor and vascular endothelial growth factor pathways

Howard Burris, Caio Rocha-Lima

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

In advanced pancreatic cancer, single-agent gemcitabine became the standard therapy approximately 10 years ago. Subsequently, combinations of gemcitabine with fluorouracil, cisplatin, irinotecan, oxaliplatin, or pemetrexed produced no clear survival benefit. Among the newer approaches, targeting human epidermal growth factor receptor (HER-1/EGFR) shows promise. The U.S. Food and Drug Administration recently approved erlotinib (a HER-1/EGFR tyrosine kinase inhibitor) combined with gemcitabine for the first-line treatment of advanced pancreatic cancer. This combination showed a statistically significant survival benefit over gemcitabine alone in locally advanced or metastatic disease (the median overall survival time was 6.24 months versus 5.91 months; hazard ratio, 0.82; p = .038); however, the clinical significance of this survival difference has been questioned. Additionally, a large phase III trial where the addition of cetuximab (an anti-HER-1/EGFR monoclonal antibody [mAb]) to gemcitabine failed to result in a longer overall survival time than with gemcitabine alone has been reported. Targeting vascular endothelial growth factor (VEGF) with bevacizumab (a recombinant, humanized IgG1 mAb that binds to VEGF) in combination with gemcitabine was investigated in a phase II trial, with promising outcomes that were unfortunately not supported by a subsequent phase III study. While the future treatment of pancreatic cancer may be influenced by the potential of certain biomarkers to predict better response to molecular-targeted therapies, allowing individualization of patient therapy, there are currently no clear candidates, and this remains an interesting area for further investigation.

Original languageEnglish
Pages (from-to)289-298
Number of pages10
JournalOncologist
Volume13
Issue number3
DOIs
StatePublished - Mar 1 2008

Fingerprint

gemcitabine
Pancreatic Neoplasms
Epidermal Growth Factor
Vascular Endothelial Growth Factor A
Survival
irinotecan
oxaliplatin
Therapeutics
Pemetrexed
Molecular Targeted Therapy
Antibodies, Monoclonal, Humanized
United States Food and Drug Administration
Direction compound
Epidermal Growth Factor Receptor
Fluorouracil
Protein-Tyrosine Kinases
Cisplatin
Immunoglobulin G
Biomarkers
Monoclonal Antibodies

Keywords

  • Bevacizumab
  • Cetuximab
  • Chemotherapy
  • Erlotinib
  • Pancreatic cancer
  • Sorafenib

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

New therapeutic directions for advanced pancreatic cancer : Targeting the epidermal growth factor and vascular endothelial growth factor pathways. / Burris, Howard; Rocha-Lima, Caio.

In: Oncologist, Vol. 13, No. 3, 01.03.2008, p. 289-298.

Research output: Contribution to journalArticle

@article{98638847a65940e6b3be14c736b1c9e8,
title = "New therapeutic directions for advanced pancreatic cancer: Targeting the epidermal growth factor and vascular endothelial growth factor pathways",
abstract = "In advanced pancreatic cancer, single-agent gemcitabine became the standard therapy approximately 10 years ago. Subsequently, combinations of gemcitabine with fluorouracil, cisplatin, irinotecan, oxaliplatin, or pemetrexed produced no clear survival benefit. Among the newer approaches, targeting human epidermal growth factor receptor (HER-1/EGFR) shows promise. The U.S. Food and Drug Administration recently approved erlotinib (a HER-1/EGFR tyrosine kinase inhibitor) combined with gemcitabine for the first-line treatment of advanced pancreatic cancer. This combination showed a statistically significant survival benefit over gemcitabine alone in locally advanced or metastatic disease (the median overall survival time was 6.24 months versus 5.91 months; hazard ratio, 0.82; p = .038); however, the clinical significance of this survival difference has been questioned. Additionally, a large phase III trial where the addition of cetuximab (an anti-HER-1/EGFR monoclonal antibody [mAb]) to gemcitabine failed to result in a longer overall survival time than with gemcitabine alone has been reported. Targeting vascular endothelial growth factor (VEGF) with bevacizumab (a recombinant, humanized IgG1 mAb that binds to VEGF) in combination with gemcitabine was investigated in a phase II trial, with promising outcomes that were unfortunately not supported by a subsequent phase III study. While the future treatment of pancreatic cancer may be influenced by the potential of certain biomarkers to predict better response to molecular-targeted therapies, allowing individualization of patient therapy, there are currently no clear candidates, and this remains an interesting area for further investigation.",
keywords = "Bevacizumab, Cetuximab, Chemotherapy, Erlotinib, Pancreatic cancer, Sorafenib",
author = "Howard Burris and Caio Rocha-Lima",
year = "2008",
month = "3",
day = "1",
doi = "10.1634/theoncologist.2007-0134",
language = "English",
volume = "13",
pages = "289--298",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - New therapeutic directions for advanced pancreatic cancer

T2 - Targeting the epidermal growth factor and vascular endothelial growth factor pathways

AU - Burris, Howard

AU - Rocha-Lima, Caio

PY - 2008/3/1

Y1 - 2008/3/1

N2 - In advanced pancreatic cancer, single-agent gemcitabine became the standard therapy approximately 10 years ago. Subsequently, combinations of gemcitabine with fluorouracil, cisplatin, irinotecan, oxaliplatin, or pemetrexed produced no clear survival benefit. Among the newer approaches, targeting human epidermal growth factor receptor (HER-1/EGFR) shows promise. The U.S. Food and Drug Administration recently approved erlotinib (a HER-1/EGFR tyrosine kinase inhibitor) combined with gemcitabine for the first-line treatment of advanced pancreatic cancer. This combination showed a statistically significant survival benefit over gemcitabine alone in locally advanced or metastatic disease (the median overall survival time was 6.24 months versus 5.91 months; hazard ratio, 0.82; p = .038); however, the clinical significance of this survival difference has been questioned. Additionally, a large phase III trial where the addition of cetuximab (an anti-HER-1/EGFR monoclonal antibody [mAb]) to gemcitabine failed to result in a longer overall survival time than with gemcitabine alone has been reported. Targeting vascular endothelial growth factor (VEGF) with bevacizumab (a recombinant, humanized IgG1 mAb that binds to VEGF) in combination with gemcitabine was investigated in a phase II trial, with promising outcomes that were unfortunately not supported by a subsequent phase III study. While the future treatment of pancreatic cancer may be influenced by the potential of certain biomarkers to predict better response to molecular-targeted therapies, allowing individualization of patient therapy, there are currently no clear candidates, and this remains an interesting area for further investigation.

AB - In advanced pancreatic cancer, single-agent gemcitabine became the standard therapy approximately 10 years ago. Subsequently, combinations of gemcitabine with fluorouracil, cisplatin, irinotecan, oxaliplatin, or pemetrexed produced no clear survival benefit. Among the newer approaches, targeting human epidermal growth factor receptor (HER-1/EGFR) shows promise. The U.S. Food and Drug Administration recently approved erlotinib (a HER-1/EGFR tyrosine kinase inhibitor) combined with gemcitabine for the first-line treatment of advanced pancreatic cancer. This combination showed a statistically significant survival benefit over gemcitabine alone in locally advanced or metastatic disease (the median overall survival time was 6.24 months versus 5.91 months; hazard ratio, 0.82; p = .038); however, the clinical significance of this survival difference has been questioned. Additionally, a large phase III trial where the addition of cetuximab (an anti-HER-1/EGFR monoclonal antibody [mAb]) to gemcitabine failed to result in a longer overall survival time than with gemcitabine alone has been reported. Targeting vascular endothelial growth factor (VEGF) with bevacizumab (a recombinant, humanized IgG1 mAb that binds to VEGF) in combination with gemcitabine was investigated in a phase II trial, with promising outcomes that were unfortunately not supported by a subsequent phase III study. While the future treatment of pancreatic cancer may be influenced by the potential of certain biomarkers to predict better response to molecular-targeted therapies, allowing individualization of patient therapy, there are currently no clear candidates, and this remains an interesting area for further investigation.

KW - Bevacizumab

KW - Cetuximab

KW - Chemotherapy

KW - Erlotinib

KW - Pancreatic cancer

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=43549094700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549094700&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2007-0134

DO - 10.1634/theoncologist.2007-0134

M3 - Article

C2 - 18378539

AN - SCOPUS:43549094700

VL - 13

SP - 289

EP - 298

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -